MG K10
Alternative Names: MG-K10Latest Information Update: 13 May 2024
At a glance
- Originator Shanghai Mabgeek Biotech
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Atopic dermatitis
- Phase I/II Asthma
Most Recent Events
- 08 Mar 2024 Efficacy and adverse event data from a phase II trial in Atopic dermatitis presented at the American Academy of Dermatology annual Meeting 2024 (AAD-2024)
- 23 Oct 2023 Shanghai Mabgeek Biotech initiates phase I pharmacokinetics trial (In adults) in China (NCT06277284)
- 13 Jul 2023 Phase-III clinical trials in Atopic dermatitis (Treatment-experienced, In adolescents, In adults, In the elderly) in China (SC) (NCT06026891)